Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Infections are reported in up to 19% of pembrolizumab treated patients across clinical trials and in 7–100% in the standard of care population receiving various immune checkpoint inhibitor therapies. Risk factors for infection development remains controversial but among them include...

Descripción completa

Detalles Bibliográficos
Autores principales: Burns, Ethan A., Gee, Kelly, Kieser, Ryan B., Xu, Jiaqiong, Zhang, Yuqi, Crenshaw, Aubrey, Muhsen, Ibrahim N., Mylavarapu, Charisma, Esmail, Abdullah, Shah, Shivan, Umoru, Godsfavour, Sun, Kai, Guerrero, Carlo, Gong, Zimu, Heyne, Kirk, Singh, Monisha, Zhang, Jun, Bernicker, Eric H., Abdelrahim, Maen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817839/
https://www.ncbi.nlm.nih.gov/pubmed/36612078
http://dx.doi.org/10.3390/cancers15010081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817839/
https://www.ncbi.nlm.nih.gov/pubmed/36612078
http://dx.doi.org/10.3390/cancers15010081

Ejemplares similares